QuidelOrtho is a pure-play diagnostics company that develops and manufactures technologies for detecting diseases and health conditions, including HIV, hepatitis C, flu, strep, and COVID-19. Its work is grounded in immunoassay and molecular testing, with a history that includes pioneering the earliest lateral-flow pregnancy test strips, obtaining the first FDA-approved rapid antigen diagnostic test for Influenza, and developing one of the earliest molecular PCR assays for SARS-CoV-2.
The company operates across more than 120 years of collective experience in the diagnostics field. Its technologies are deployed in point-of-care settings, clinical laboratories, and transfusion medicine environments worldwide.
QuidelOrtho's stated mission is developing and manufacturing innovative diagnostic technologies, with a focus on expanding access to testing across diverse healthcare settings.
